Answers are grounded in this paper and cite their sources.
Background Insomnia symptoms are common among individuals with overweight and obesity, yet their clinical significance in this population remains insufficiently understood. In particular, it remains unclear whether insomnia symptoms may serve as a marker of the multidimensional comorbidities associated with excess body weight, including psychiatric symptoms, impaired quality of life, and metabolic disturbances. Methods A total of 97 adult outpatients eligible for a weight management intervention were enrolled in this cross-sectional study. Participants underwent anthropometric and laboratory assessments and completed self-report questionnaires evaluating insomnia symptoms (Athens Insomnia Scale, AIS), daytime sleepiness (Epworth Sleepiness Scale), depressive symptoms (Patient Health Questionnaire-9), anxiety symptoms (Generalized Anxiety Disorder-7), quality of life (EuroQol 5-Dimension 5-Level Questionnaire), and food addiction symptoms (Modified Yale Food Addiction Scale 2.0). Results Participants with insomnia symptoms constituted 56.7% of the study sample. Compared with those without insomnia symptoms, they demonstrated significantly higher levels of depressive and anxiety symptoms, daytime sleepiness, poorer quality of life, and higher prevalence and severity of food addiction. No positive correlation was observed between insomnia symptoms and BMI or metabolic parameters. Conclusions These findings suggest that insomnia symptoms may represent a clinically relevant marker of psychiatric and behavioral burden in this population and highlight the potential value of routine screening for insomnia symptoms in obesity management clinics. Level of evidence Level III: Evidence obtained from well-designed cohort or case-control analytic studies.
No takes yet. Share an insight, caveat, or question.
Lis et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: